CDER Launches the ARC Program to Expedite Treatment Options for Rare Diseases
In May 2022, the Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA) announced the launch of a new program for expediting the development of new treatment options for rare diseases—Accelerating Rare disease Cures (ARC) Program.1 The FDA considers a disease that affects fewer than 200,000 people in the U.S. a rare disease, and estimates that more than 30…
Evaf Yincontributed Critical Path Institute Drug Administration Drug Or Rare Pediatric Disease Designation Program Drug Evaluation Accelerating Rare
Source: wsgr.com